Secondary cancers following CAR T cell therapy are rare, analysis shows

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine. Researchers from the Perelman School of Medicine at the University of Pennsylvania report their findings in Nature Medicine.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.